Avoro Capital Advisors LLC Makes New $25.42 Million Investment in Septerna, Inc. (NASDAQ:SEPN)

Avoro Capital Advisors LLC bought a new position in shares of Septerna, Inc. (NASDAQ:SEPN - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 1,110,000 shares of the company's stock, valued at approximately $25,419,000. Avoro Capital Advisors LLC owned 2.50% of Septerna at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in SEPN. TRV GP V LLC acquired a new position in shares of Septerna in the fourth quarter worth approximately $142,337,000. TRV GP VI LLC bought a new position in Septerna during the 4th quarter worth approximately $72,191,000. Vanguard Group Inc. acquired a new position in shares of Septerna in the 4th quarter worth approximately $22,557,000. Geode Capital Management LLC bought a new stake in shares of Septerna in the 4th quarter valued at $8,717,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of Septerna during the fourth quarter worth $3,197,000.

Insider Buying and Selling at Septerna

In other Septerna news, CFO Gil M. Labrucherie acquired 5,000 shares of the company's stock in a transaction on Friday, February 21st. The shares were purchased at an average cost of $5.85 per share, with a total value of $29,250.00. Following the completion of the purchase, the chief financial officer now owns 30,000 shares of the company's stock, valued at approximately $175,500. This represents a 20.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Alan Ezekowitz bought 7,491 shares of the firm's stock in a transaction dated Tuesday, March 4th. The shares were acquired at an average cost of $6.35 per share, with a total value of $47,567.85. Following the completion of the transaction, the director now owns 24,911 shares of the company's stock, valued at $158,184.85. This represents a 43.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 74,346 shares of company stock valued at $439,670.

Septerna Stock Performance

NASDAQ SEPN remained flat at $6.46 on Friday. 173,738 shares of the company traded hands, compared to its average volume of 428,560. The business has a 50 day moving average price of $5.95. Septerna, Inc. has a fifty-two week low of $4.17 and a fifty-two week high of $28.99.

Septerna (NASDAQ:SEPN - Get Free Report) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.69) by $0.05. The company had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.13 million. As a group, equities analysts anticipate that Septerna, Inc. will post -7.11 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Wells Fargo & Company dropped their target price on shares of Septerna from $14.00 to $11.00 and set an "equal weight" rating on the stock in a report on Friday, March 28th. Cantor Fitzgerald reissued an "overweight" rating and issued a $50.00 price objective on shares of Septerna in a research note on Tuesday, February 11th.

Septerna Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.